Depósito Digital de Documentos de la UAB Encontrados 4 registros  La búsqueda tardó 0.00 segundos. 
1.
12 p, 1.8 MB Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL : 5 years of follow-up from the phase 3 RESONATE-2 study / Burger, Jan A. (University of Texas MD Anderson Cancer Center. Department of Leukemia) ; Barr, Paul M. (Wilmot Cancer Institute, University of Rochester Medical Center) ; Robak, Tadeusz (Medical University of Lodz, Copernicus Memorial Hospital) ; Owen, Carolyn (University of Calgary. Tom Baker Cancer Centre) ; Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy) ; Bairey, Osnat (Tel Aviv University. Rabin Medical Center, Petah Tikva, Israel and Sackler Faculty of Medicine) ; Hillmen, Peter (University of Leeds. The Leeds Teaching Hospitals, St. James Institute of Oncology) ; Coutre, Steven E. (Stanford University School of Medicine. Stanford Cancer Center) ; Devereux, Stephen (NHS Foundation Trust. Kings College Hospital) ; Grosicki, Sebastian (Silesiam Medical University. Department of Hematology and Cancer Prevention) ; McCarthy, Helen (Royal Bournemouth General Hospital) ; Simpson, David (North Shore Hospital) ; Offner, Fritz (Universitair Ziekenhuis Gent) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Dai, Sandra (Pharmacyclics LLC, an AbbVie Company) ; Lal, Indu (Pharmacyclics LLC, an AbbVie Company) ; Dean, James P. (Pharmacyclics LLC, an AbbVie Company) ; Kipps, Thomas J. (UCSD Moores Cancer Center) ; Universitat Autònoma de Barcelona
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0. [...]
2019 - 10.1038/s41375-019-0602-x
Leukemia, Vol. 34 (october 2019) , p. 787-798  
2.
8 p, 788.7 KB A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS) / Hájek, R. (University Hospital Ostrava) ; Masszi, T (St István and St László Hospital of Budapest) ; Petrucci,M.T. (Sapienza Università di Roma) ; Palumbo, A. (Università di Torino) ; Rosiñol, L. (Hospital Clínic de Barcelona) ; Nagler, Arnon. (Chaim Sheba Medical Center (Israel)) ; Yong, K.L. (University College London Cancer Institute) ; Oriol, A. (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; Minarik, J. (University Hospital Olomouc and Medical Faculty of Palacky) ; Pour, L (University Hospital Ostrava) ; Dimopoulos, M.A. (National and Kapodistrian University of Athens) ; Maisnar, V. (Charles University Teaching Hospital, Hradec Králové) ; Rossi, D. (Amedeo Avogadro University of Eastern Piedmont) ; Kasparu, H. (Hospital Elisabethinen Linz) ; Van Droogenbroeck, J. (AZ Sint-Jan, Brugge, Belgium) ; Yehuda, D.B. (Hadassah Medical Center, Jerusalem, Israel) ; Hardan, I. (Meir Medical Center, Kfar-Saba, Israel) ; Jenner, M. (Southampton General Hospital, Hampshire, UK) ; Calbecka, M. (Nicolaus Copernicus Hospital, Toruń Poland) ; Dávid, M. (University of Pécs, Hungary) ; de la Rubia, J. (Hospital Universitario La Fe, València) ; Drach, J. (Medical University of Vienna) ; Gasztonyi, Z. (Petz Aladár Megyei Oktató Kórház, Vasvári Pál, Hungary) ; Górnik, S. (Zamojski Szpital Niepubliczny, Zamosc, Poland) ; Leleu, X. (Hopital Huriez, CHRU, Lille, France) ; Munder, M. (University Medicine Mainz, Germany) ; Offidani, M (Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Italy) ; Zojer, N. (Center for Oncology, Hematology with Outpatient Department and Palliative Care, Wilhelminenspital, Vienna, Austria) ; Rajangam, K. (Onyx Pharmaceuticals, Inc.) ; Chang, Y.L. (Onyx Pharmaceuticals, Inc.) ; San-Miguel, J.F. (Clínica Universidad de Navarra-CIMA-IDISNA) ; Ludwig, H. (Wilhelminen Cancer Research Institute, Vienna, Austria)
This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). [...]
2017 - 10.1038/leu.2016.176
Leukemia, Vol. 31 (2017) , p. 107-114  
3.
11 p, 693.2 KB ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation / Malcikova, J. (Brno, Czech Republic) ; Tausch, E. (Ulm, Germany) ; Rossi, D. (Bellinzona, Switzerland) ; Sutton, L. A. (Stockholm, Sweden) ; Soussi, T. (Stockholm, Sweden) ; Zenz, T. (Zürich, Switzerland) ; Kater, A. P. (Amsterdam, The Netherlands) ; Niemann, C. U. (Copenhagen, Denmark) ; González De Castro, David (Belfast, UK) ; Davi, F. (Paris, France) ; Gonzalez Diaz, M. (Salamanca, Spain) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Gaidano, G. (Novara, Italy) ; Stamatopoulos, K. (Thessaloniki, Greece) ; Rosenquist, R. (Stockholm, Sweden) ; Stilgenbauer, S. (Ulm, Germany) ; Ghia, P. (Milan, Italy) ; Pospisilova, S. (Brno, Czech Republic) ; Universitat Autònoma de Barcelona
In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with resistance to chemoimmunotherapy and a particularly dismal clinical outcome. [...]
2018 - 10.1038/s41375-017-0007-7
Leukemia, Vol. 32 (february 2018) , p. 1070-1080  
4.
4 p, 471.8 KB Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia / Anadón, C (Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; van Tetering, G (Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Ferreira, H J (Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Moutinho, C (Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Martínez-Cardús, A (Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Villanueva, A (Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Soler, M (Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Heyn, H (Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Moran, S (Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Castro de Moura, M (Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Setien, F (Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Vidal, A (Department of Pathological Anatomy, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Genescà, E (Institut Germans Trias i Pujol) ; Ribera, J M (Institut Germans Trias i Pujol) ; Nomdedéu Guinot, Josep Francesc (Institut d'Investigació Biomèdica Sant Pau) ; Guil, S (Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Esteller, M (Institucio Catalana de Recerca i Estudis Avançats (ICREA)) ; Universitat Autònoma de Barcelona
2017 - 10.1038/leu.2017.99
Leukemia, Vol. 31 (04 2017) , p. 1622-1625  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.